MURPHY ANDREW J sold $4.8M of REGN

MURPHY ANDREW J (Co-Chief Scientific Officer) sold 5,011 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $957.76 ($949.69–$964.36, $4.80M total) across 16 trades on 2026-11-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MURPHY ANDREW J
Published Nov 18, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

This provides a transparent datapoint on insider behavior, but it does not disclose new operational, clinical, regulatory, or financial guidance for Regeneron.

02

Market read

For traders, the main use is sentiment and positioning context, not a fundamental catalyst.

03

What to watch

Traders may also consider whether the insider’s remaining holdings (46,779 shares after sale) and any prior insider activity suggest a broader pattern, rather than treating this single sale as a directional signal.

Relevance 5/10Novelty 6/10Timing: SEC Form 4 filed 2026-11-18, covering sales executed 2026-11-17.

Background

The article is an SEC Form 4 insider transaction: Andrew J. Murphy (Co-Chief Scientific Officer) sold REGN shares in multiple trades on 2026-11-17 under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Regeneron co-chief scientific officer Andrew J. Murphy sold about $4.8M of REGN shares via a 10b5-1 plan on 2026-11-17.

Expected impact

Likely limited impact; any short-term pressure would be more sentiment-driven than driven by new company fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it is an open-market sale under a pre-arranged 10b5-1 plan, which usually reduces interpretive weight versus discretionary selling.

Market effects

Biopharma insider-sale disclosures can slightly influence sentiment around large-cap biotech, but this specific filing does not indicate a sector-wide catalyst.

No direct regional market linkage beyond US large-cap biotech sentiment.

Minimal global relevance; this is company-specific insider transaction data.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, the market may overreact; price impact could be negligible once traders recognize the pre-arranged nature.

Key entities

  • REGN

    Regeneron Pharmaceuticals, Inc., issuer of the Form 4 insider sale.

  • Andrew J. Murphy

    Co-Chief Scientific Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.